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a  b  s  t  r  a  c  t
Background: For radioimmunotherapy purposes, a chemical complex with high absorption
in  cancer tumor is required. New chemicals are to be examined for their concentration in
tumor and healthy organs. These are labeled with -emitting radioisotopes to irradiate the
tumor while deposited inside it.
Aim: To study the capability of recently developed chemical complex in targeting cancer
tumor and investigate the distribution of 153Sm-TPTTC in rat organs as function of time.
Materials and methods: The chemical complex – [Tris(1,10-phenanthroline)Samarium(III)]
trithiocyanate was prepared and labeled with 153Sm radioisotope. The labeled complex was
injected to a population of tumor bearing mice. In 2, 4, 24, 48, 96 h after injection the ani-
mals were sacriﬁced and the concentration of Samarium complex was measured in various
organs such as blood, heart, intestine, colon, liver, spleen, kidney, sternum and bone.
Results: The concentration of the radiopharmaceutical in various organs was measured at
different times. The temporal behavior of biodistribution of 153Sm-TPTTC was modeled and
drawn as function of time.
Conclusion: It is shown that 153Sm-TPTTC is concentrated in tumor tissue and liver muchmore  than in other organs. The variation of pharmaceutical concentration in all organs is
described with summation of eight exponential terms and it approximates our experimental
data with precision better than 2%.
© 2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
of 46.8 h. Emitted beta ray energies and their abundances are1.  Background
Targeted radiotherapy has been developing over past two
decades.1,2 In this method, a major proportion of radiation is
delivered directly to the cancerous tumor by biological means.
The chemical compound with high deposition in tumor is
labeled with a beta emitter radioisotope. The high LET (linear
energy transfer) of beta particle leads to destruction of cancer
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cells while the radioisotope is concentrated inside the tumor.
The short range of beta particle spares the healthy tissue sur-
rounding the tumor and the major proportion of the radiation
dose is absorbed by the tumor.
Among beta emitting radioisotopes is 153Sm with half-life(D. Sardari).
640 keV (30%), 710 keV (50%), and 810 keV (20%), respectively.
Average beta ray energy of 290 keV renders the penetration
depth of 3 mm in soft tissue, making it a good candidate for
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 2. The compartmental model7–10 was used to produce anown as Sm-TPTTC.
pplication in targeted radiotherapy. Besides beta ray, 153Sm
mits gamma radiation and conversion electrons with 103 keV
nd 55 keV energies, respectively.3 Gamma  ray at this energy
ange makes nuclear imaging feasible, while the process of
adiotherapy is carried out. Finally, 153Sm decays to stable
uclide 153Eu.
.  Aim
amarium, being a Lanthanide metal, concentrates in bone,
specially tissues with high osteoblastic activity. This gives the
eneﬁt of its absorption in metastatic tissues in bone cancer.
s a rule of thumb, concentration of Samarium in metastatic
one tissues is ﬁve times higher than in normal tissue.4
Sm-EDTMP has already been produced in our laboratory.5
n this work, 153Sm-[Tris(1,10-phenanthroline)Samarium(III)]
rithiocyanate (153Sm-TPTTC) was developed for possible
herapeutic applications (Fig. 1) and the variation of its con-
entration with time in important organs is shown.
.  Materials  and  methods
.1.  Radionuclide  production
table Samarium, 152Sm,  is a Lanthanide with high absorp-
ion cross section for thermal neutrons (204 barns) leading
o production of 153Sm.  The radionuclide was prepared in a
esearch reactor according to regular methods with a speciﬁc
ctivity of 350 mCi/mg for radiolabeling use. The radioiso-
ope was dissolved in acidic media as a starting sample and
as further diluted and evaporated to obtain the desired pH
nd volume followed by sterile ﬁltering. Gamma-ray spectrum
evealed the presence of 154Eu (<4.7 × 10−5% of 153Sm)  and
55Eu (<2.4 × 10−5% of 153Sm)  at the end of irradiation.Radiochemical impurities in the 153Sm sample in the radi-
labeling step were checked by two systems. As stationary
hase for paper chromatography system, Whatman 2 mmtherapy 1 7 ( 2 0 1 2 ) 358–362 359
paper was utilized.6 In 10% ammonium acetate:methanol, the
free Samarium cation in 153Sm3+ form remains at the origin
(Rf = 0.0), while other 153Sm species migrate to higher (Rf = 0.8).
Another agent for Sm3+ detection was 10 mM DTPA aqueous
solution at pH 4 (Rf = 0.8).
3.2.  Biodistribution  of 153Sm-TPTTC  in  tumor  bearing
mice
The ﬁrst stage in examining a new pharmaceutical is to study
its behavior and effects in the body of a mouse or rat. Due  to
physiological resemblance between rat and human, the distri-
bution of drugs in a rat body is a good indicator of phenomena
appearing in a human body. Thus, the information collected
by animal experiments would be applicable for development
of pharmaceuticals for human.6
In the present study, the biological distribution of newly
developed Sm-TPTTC complex in healthy and tumor bearing
rats was evaluated.
Fibrosarcoma cells (about 104) were injected s.c. to the dor-
sal area of Balb/C mice weighing 15–20 g. The distribution of
153SmCl3 and 153Sm-TPTTC among tissues were determined
for untreated mice and for mice with Fibrosarcoma. Brieﬂy,
a volume (0.1 ml)  of ﬁnal 153Sm-TPTTC solution containing
(3.5–3.8 × 106 Bq) radioactivity was injected intravenously into
the dorsal tail vein. The animals were sacriﬁced at the exact
time (2, 4, 24, 48, 96 h) after injection and speciﬁc activities
of different organs were measured as percentage of injected
dose per gram of tissue using HPGe detector (%ID/g). The ani-
mals were sacriﬁced by asyxphycation at selected times after
injection, the tissues were weighed and their speciﬁc activities
were determined with scintillation detectors as percentage of
injected dose per gram of tissues.
The total amount of radioactivity injected into each mouse
was measured by counting 1-ml syringe before and after injec-
tion in a radiometer with a ﬁxed geometry. 153Sm-TPTTC was
prepared in two steps. At ﬁrst, 153SmCl3 was produced by neu-
tron irradiation of an enriched 152Sm sample in a research
nuclear reactor. Biodistribution studies of the complex in wild-
type rats and tumor bearing mice were also determined. The
radiolabeled complex was prepared in high radiochemical
purity (>99% precipitation method) and speciﬁc activity of
278 GBq/mmol and demonstrated signiﬁcant stability at 4, 25
and 37 ◦C (in the presence of human serum). Initial biodistribu-
tion data showed signiﬁcant liver accumulation in wild-type
rat and tumor accumulation in tumor bearing mice of the
tracer in 48 h. The properties of 153Sm-TPTTC products sug-
gest an efﬁciently new liver accumulating therapeutic agent in
order to overcome possible liver malignancies with the lowest
toxicity.
4.  Results
The activity concentration in each organ was measured
with the use of detectors at speciﬁed time after injection.
The results show variation with time which is depicted inmathematical description of these variations. The following
equations were obtained for each organ. In each case, t = 0
corresponds to the time of injection.
360  reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 358–362
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(1) Blood
1 = 2.6824 e−1.64t + (5.844E − 5) e−0.06t + (4.075E − 2) e0.025t
− (4.7201E − 2) e−5.04t − (4.5559E − 6) e−1.64t
− (5.1499E − 6) e−0.14t − (4.94E − 3) e0.051t
(2) Heart
2 = (9.512E  − 1) e−0.001t + (4.408E − 1) e−(9.9E−5)t
− (9.28E  − 3) e0.049t − (4.118E − 4) e−5.04t
− (4.0194E − 4) e−1.64t − (6.264E − 4) e−0.14t
− (7.598E  − 4) e−0.06t
(3) Sternum
3 = (8.736E  − 1) e−0.001t + (3.172E − 1) e−(9.9E−5)t
− (1.092E  − 2) e0.042t − (4.212E − 4) e−5.04t
− (5.09656836E − 2) e−1.64t − (5.616E − 4) e−0.14t
− (2.5532E − 3) e−0.06t
(4) Liver
4 = (8.0444E − 5) e−0.06t + 3.6924 e−(9.9E−5)t − (6.80E  − 3) e0.051t
− (6.4974E − 2) e−5.04t − (6.2968E − 6) e−1.64t
− (7.089E  − 6) e−0.14t
(5) Bone
5 = (6.888E  − 1) e−0.001t + (3.192E − 1) e−(9.9E−5)t
− (1.26E  − 2) e0.04032t − (2.982E − 4) e−5.04t
− (2.9106E − 5) e−1.64t − (4.536E − 4) e−0.14t
− (5.502E  − 3) e−0.06t
(6) Kidney
6 = (4.090814E − 5) e−0.06t + 1.877694 e(9.9E−5)t
+ (2.85285E  − 2) e0.025t − (3.9767E − 3) e0.051t
− (3.375008E  − 6) e−1.64t − (3.604965E − 6) e−0.14t
− (3.321409E  − 1) e−5.04t
(7) Spleen
7 = (6.61608E  − 2) e0.06t + 5.95243 e−1.64t + (7.52477E − 2) e−0.14t
+ (4.9008E − 1) e0.019t + (5.7176E − 1) e−0.091t
− 5.70739 e−5.04t
(8) Colon8 = (2.752E  − 5) e−0.06t + 0.1304 e(−9.9E−4)t + (1.568E − 5) e−0.001t
− (2.272E  − 8) e−0.14t − (1.48E − 5) e−5.04ttherapy 1 7 ( 2 0 1 2 ) 358–362 361
(9) Intestine
f9 = (1.96424E − 4) e−0.06t + (9.3073E − 1) e(−9.9E−4)t
+ (1.11916E − 4) e−0.001t + (4.568E  − 1) e − 0.077t
− (1.62164E − 7) e−0.14t − (1.05635E − 4) e−5.04t
(10) Tumor
f10 = (1.8928E − 4) e−0.06t + 8.688 e(−9.9E−4)t − (1.668E − 5) e−0.14t
− (1.5288E − 1) e−5.04t − (1.4816E − 5) e−1.64t
− (1.60E  − 2) e0.51t
153Sm-TPTTC imaging performed in the tumor-bearing mice
showed a distinct accumulation of the radiotracer in the
tumor, while in the ﬁrst and second hour a background in the
liver was absorbed (Fig. 2).
5.  Discussion
Among many  Samarium compounds, such as EDTA, DTPA,
EDTMP, DTPMP, and HEDTA, Sm-153-EDTMP is proven to be a
better choice in treatment of metastatic bone cancer11,12 and
is already been used in clinical practice. The criteria to choose
this compound were its blood clearance, little concentration in
other organs, and practical pain relief in cancer patients. 153Sm
was used for pain relief in patients with bone metastases. It
was administered proportionally to body weight (37 MBq/kg)
in 50 patients, 30 of them in combination with external beam
radiation therapy. Complete pain relief was observed in 40%
of patients, a more  satisfactory ﬁgure compared with 89Sr.13
Although considered as a negative effect in EDTMP,  the
remarkable concentration of TPTTC in the liver makes it a
good candidate for treatment of liver cancer. The ID/g con-
centration of TPTTC in the liver is 3 times higher than that in
bone. One disadvantage of 153Sm-TPTTC is its slow blood clear-
ance (Fig. 2). In such a case, drinking high amount of liquids is
recommended for the patient.
6. Conclusion
Beta emitter radioisotope of a rare earth metal, Samarium,
153Sm,  can destroy cancer cells due to its radiation, if deposited
inside the tumor. Using nuclear imaging techniques, it was
shown that the labeled compound 153Sm-TPTTC concentrates
in tumor tissue and is a proper candidate for targeted radioim-
munotherapy. Concentration of 153Sm-TPTTC in important
organs of tumor bearing mice was measured at time intervals
of up to 96 h. It was concluded that its concentration depicts
various behavior as function of time in different organs. In
the blood, the concentration of radiopharmaceutical increases
up to 60 h after injection and after that a sharp decrease is
observed. In the heart, the variation is monotonically decreas-
ing and the rate of decrement becomes faster at longer times
after injection. The same trend is observed in the liver, ster-
num, bone and tumor, in the sternum and bone the fall-off
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concentration in tumor is desirably constant until 50 h after
injection and decreases to 65% of initial value after 96 h. In
the spleen, after a rapid decrease, a minimum is observed at
t = 15 h after which the concentration curve tends to soar up
to reach a level a few times higher than the initial one. Finally,
it is concluded that 153Sm-TPTTC might be considered in the
future as a radiopharmaceutical for targeted radiotherapy of
cancerous tissues located in the liver. For this purpose, more
pre-clinical stages, such as rabbit experiment and human tox-
icity tests must be performed.
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